Integration of molecular targeted therapy with radiation in head and neck cancer

被引:37
|
作者
Du, Yu [1 ,3 ]
Peyser, Noah D. [1 ,2 ]
Grandis, Jennifer R. [1 ,2 ]
机构
[1] Univ Pittsburgh, Sch Med, Dept Otolaryngol, Pittsburgh, PA 15213 USA
[2] Univ Pittsburgh, Sch Med, Dept Pharmacol & Chem Biol, Pittsburgh, PA 15213 USA
[3] Tsinghua Univ, Sch Med, Beijing 100084, Peoples R China
关键词
Head and neck squamous cell carcinoma; Radiotherapy; Molecular targeted therapy; Preclinical models; Clinical trials; Epidermal growth factor receptor; SQUAMOUS-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; LOCALLY ADVANCED HEAD; PROTEASOME INHIBITOR BORTEZOMIB; RANDOMIZED PHASE-II; CONCURRENT CHEMORADIOTHERAPY; MONOCLONAL-ANTIBODY; DNA-REPAIR; HSP90; INHIBITOR; POOR-PROGNOSIS;
D O I
10.1016/j.pharmthera.2013.11.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Approximately 600,000 new cases of head and neck cancer arise worldwide each year. Of these, a large majority are head and neck squamous cell carcinomas (HNSCC). Conventional treatments, including surgical excision followed by radiation and/or chemoradiotherapy have limited efficacy and are associated with substantial toxicity. To date, key targets for molecular targeted therapy in HNSCC are epidermal growth factor receptors and angiogenesis-related factors. Cetuximab is a monoclonal antibody targeting the epidermal growth factor receptor (EGFR) and it is the only targeted therapy approved by the United States Food and Drug Administration for the treatment of HNSCC. Cetuximab in combination with radiotherapy represents a standard approach for newly diagnosed patients who are unable to tolerate platinum chemotherapy. Despite efficacy in preclinical HNSCC models, cetuximab is only effective in a subset of HNSCC patients, most likely due to the high heterogeneity of this cancer. Additional targets under active investigation include the PI3K/Akt pathway, the Ras-MAPK-ERK pathway and the JAK/STAT pathway, among others. Combining molecular targeted therapies and radiation may allow for deintensification of radiotherapy thereby reducing radiation toxicities and improving treatment outcomes. Here we review the preclinical and clinical data in support of treatment strategies that combined targeted therapy with radiation in HNSCC. (c) 2013 Elsevier Inc. All rights reserved.
引用
收藏
页码:88 / 98
页数:11
相关论文
共 50 条
  • [1] Molecular targeted therapy for head and neck cancer
    Vermorken, Jan B.
    [J]. ANNALS OF ONCOLOGY, 2015, 26 : 33 - 33
  • [2] Integration of biomarkers including molecular targeted therapies in head and neck cancer
    Williams M.D.
    [J]. Head and Neck Pathology, 2010, 4 (1) : 62 - 69
  • [3] Targeted therapy in head and neck cancer
    Kundu, S. K.
    Nestor, M.
    [J]. TUMOR BIOLOGY, 2012, 33 (03) : 707 - 721
  • [4] Targeted therapy in head and neck cancer
    Bianchini, Chiara
    Ciorba, Andrea
    Pelucchi, Stefano
    Piva, Roberta
    Pastore, Antonio
    [J]. TUMORI, 2011, 97 (02) : 137 - 141
  • [5] Targeted Therapy in Head and Neck Cancer
    Ward, Brent B.
    [J]. ORAL AND MAXILLOFACIAL SURGERY CLINICS OF NORTH AMERICA, 2013, 25 (01) : 83 - +
  • [6] Targeted Therapy of Head and Neck Cancer
    Rieke, Damian T.
    Klinghammer, Konrad
    Keilholz, Ulrich
    [J]. ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 (12) : 780 - 786
  • [7] Targeted therapy in head and neck cancer
    Oeztop, Ilhan
    [J]. UHOD-ULUSLARARASI HEMATOLOJI-ONKOLOJI DERGISI, 2008, 18 (01): : 46 - 56
  • [8] Targeted therapy in head and neck cancer
    Licitra, Lisa
    Bergamini, Cristiana
    Mirabile, Aurora
    Granata, Roberta
    [J]. CURRENT OPINION IN OTOLARYNGOLOGY & HEAD AND NECK SURGERY, 2011, 19 (02): : 132 - 137
  • [9] Molecular targeted therapy: novel therapeutic approach for head and neck cancer
    Shrivastava, Swatantra
    Nagi, Ravleen
    Sharma, Saurabh
    Sanadi, Sajid Ahmed Rasul
    Dafallah, Elbadri Taha
    Ragit, Akshay
    [J]. THERAPEUTIC DELIVERY, 2020, 11 (10) : 637 - 651
  • [10] Progress of molecular targeted therapy for head and neck cancer in clinical aspects
    Kenji Nakano
    [J]. Molecular Biomedicine, 2